Zuzana Hassan

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Hemorrhagic cystitis: a retrospective single-center survey
    Zuzana Hassan
    Center for Allogenic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Clin Transplant 21:659-67. 2007
  2. ncbi Management of refractory hemorrhagic cystitis following hematopoietic stem cell transplantation in children
    Zuzana Hassan
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Pediatr Transplant 15:348-61. 2011
  3. ncbi Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning
    Mehmet Uzunel
    Department of Clinical Immunology, Karolinska Institute at Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Transplantation 82:913-9. 2006
  4. ncbi Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease
    Olle Ringden
    Division of Clinical Immunology, Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 90:1022-9. 2010
  5. ncbi Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen
    Sulaiman Al-Hashmi
    Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
    Int J Clin Exp Pathol 4:596-605. 2011
  6. ncbi N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro
    Helen Karlsson
    Division of Clinical Immunology, Karolinska Institutet, Stockholm, Sweden
    Eur J Immunol 41:1143-53. 2011
  7. ncbi Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study
    Mats Remberger
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 17:1688-97. 2011
  8. ncbi Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:718-25. 2006
  9. ncbi Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase
    Sulaiman Al-Hashmi
    Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 7:e30897. 2012
  10. ncbi Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006

Collaborators

Detail Information

Publications15

  1. ncbi Hemorrhagic cystitis: a retrospective single-center survey
    Zuzana Hassan
    Center for Allogenic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Clin Transplant 21:659-67. 2007
    ..With four risk factors, the risk of HC development was 31%. Risk factors for severe HC of grades 3-5 were aGVHD and bacteremia...
  2. ncbi Management of refractory hemorrhagic cystitis following hematopoietic stem cell transplantation in children
    Zuzana Hassan
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Pediatr Transplant 15:348-61. 2011
    ..As severe HC following HSCT is a potentially life-threatening complication, a multidisciplinary and individual approach is required in children suffering from this devastating complication...
  3. ncbi Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning
    Mehmet Uzunel
    Department of Clinical Immunology, Karolinska Institute at Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Transplantation 82:913-9. 2006
    ..The use of reduced intensity conditioning (RIC) regimens in allogeneic hematopoietic stem cell transplantation (HSCT) has increased over the past five years...
  4. ncbi Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease
    Olle Ringden
    Division of Clinical Immunology, Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 90:1022-9. 2010
    ..Total body irradiation and bone marrow were found to be prerequisites for acute GVHD. This study encouraged us to perform a retrospective clinical study...
  5. ncbi Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen
    Sulaiman Al-Hashmi
    Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
    Int J Clin Exp Pathol 4:596-605. 2011
    ..This is the first study describing early histopathological changes after conditioning regimen with busulphan/cyclophosphamide and dynamics of GVHD development in several major internal organs...
  6. ncbi N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro
    Helen Karlsson
    Division of Clinical Immunology, Karolinska Institutet, Stockholm, Sweden
    Eur J Immunol 41:1143-53. 2011
    ..To conclude, NAC appears to increase acute GvHD and has an immunostimulatory effect on alloantigen-specific T cells...
  7. ncbi Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study
    Mats Remberger
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 17:1688-97. 2011
    ..The problem of relapse still has to be remedied. Thus, several different developments together have resulted in significantly lower TRM and improved survival after HSCT over the last few years...
  8. ncbi Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:718-25. 2006
    ..Allogeneic hematopoietic stem cell transplantation (ASCT) is a possible cure for many inherited disorders...
  9. ncbi Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase
    Sulaiman Al-Hashmi
    Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 7:e30897. 2012
    ..This study contributes to understanding the mechanisms that underlie the early effects of conditioning regimen on resistance arteries and may help in designing further investigations to understand the late effects on vascular system...
  10. ncbi Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
    ..Mesenchymal stem cells (MSC) have immunomodulatory effects. The aim was to study the effect of MSC infusion on graft-versus-host disease (GVHD)...
  11. ncbi Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning
    Behnam Sadeghi
    Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden
    Clin Dev Immunol 2010:142943. 2010
    ..Thus, in the very early phase of GHVD following Bu-Cy conditioning donor, DCs play an important role in the activation of donor T cells. Subsequently, donor naïve T-cells gain effector-memory phenotype and initiate GVHD...
  12. ncbi Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine
    Ibrahim El-Serafi
    Experimental Cancer Medicine, Clinical Research Centre KFC, Department of Laboratory Medicine, Karolinska Institutet Huddinge, Novum, Stockholm, Sweden
    J Chromatogr B Analyt Technol Biomed Life Sci 913:98-105. 2013
    ..The method was applied in a clinical case where the patient received high dose busulphan; all the compounds have been detected, identified and quantified both in plasma and urine...
  13. ncbi The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine
    Moustapha Hassan
    Experimental Cancer Medicine ECM, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
    Sultan Qaboos Univ Med J 11:165-78. 2011
    ..Early pharmacokinetic/pharmacodynamic studies are important issues in drug discovery and may affect further development of promising drug candidates...
  14. ncbi Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice
    Christina Nilsson
    Laboratory of Hematology, Division of Hematology, Department of Medicine Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Exp Hematol 33:380-7. 2005
    ..CONCLUSION: Cy-Bu treatment resulted in lower levels of cytokines, faster bone marrow engraftment, and lower values of liver enzymes compared to Bu-Cy regimen, which may benefit stem cell transplantation outcomes...
  15. ncbi Myeloablative and immunosuppressive properties of treosulfan in mice
    Fredrik Sjöö
    Laboratory of Hematology, Karolinska Hematology Center, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Exp Hematol 34:115-21. 2006
    ..In the present preclinical study, myeloablative as well as immunosuppressive properties of treosulfan were compared with those of busulfan and cyclophosphamide...